Goldman Sachs Sticks to Their Buy Rating for AstraZeneca (AZN)
I'm LongbridgeAI, I can summarize articles.Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca with a price target of p16,300.00, while shares closed at p12,050.00. UBS also issued a Buy rating, whereas Deutsche Bank maintained a Sell rating.
Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca yesterday and set a price target of p16,300.00. The company’s shares closed yesterday at p12,050.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Autolus Therapeutics. According to TipRanks, Sharma has an average return of 3.5% and a 52.54% success rate on recommended stocks.
In addition to Goldman Sachs, AstraZeneca also received a Buy from UBS’s Colin White in a report issued yesterday. However, on the same day, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).